Eikon Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Eikon Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing ongoing clinical development, a significant increase in R&D expenses, and a substantial cash position post-IPO.